Bright Eye Hospital Group Analysis (March 2026) | Price Development & Price Target

Bright Eye Hospital ...

SZSE:301239

HK$ 33,71

+ HK$0,54 (1,63%)

33,71 HK$

+HK$0,54 (1,63%)

End-of-day quote: 03/27/2026

Bright Eye Hospital Group Stock Value

The analyst rating for SZSE:301239 is currently Buy.

Buy

Bright Eye Hospital Group Company Info

EPS Growth 5Y

0,00%

Market Cap

HK$5,02 B

Long-Term Debt

HK$0,10 B

Quarterly earnings

04/22/2026

Dividend

HK$0,00

Dividend Yield

0,00%

Founded

2006

Industry

Health Care

Country

China

Website

Bright Eye Hospital Group

ISIN Number

CNE100005GX3

Website

http://www.purui.cn

Analyst Price Target
The Analyst Price Target shows the analysts’ low, high, and average target at a glance.

HK$45,33

34.47%

Last Update: 03/29/2026

Analysts: 1

Highest Price Target HK$45,33

Average Price Target HK$45,33

Lowest Price Target HK$45,33

In the last five quarters, Bright Eye Hospital Group’s Price Target has risen from HK$107,68 to HK$107,68 - a 0,00% increase.

Top growth stocks in the health care sector (5Y.)

What does Bright Eye Hospital Group do?

Bright Eye Hospital Group Co., Ltd., a specialized chain medical institution company, engages in the provision of ophthalmic general medical services. Business Segments The company’s business is structured around several core segments, each designed to address the diverse needs of patients seeking specialized eye care services. The company’s primary business segments include refractive surgery, cataract surgery, optometry, comprehensive ocular disease management, and other related medical serv...

Bright Eye Hospital Group Co., Ltd., a specialized chain medical institution company, engages in the provision of ophthalmic general medical services.

Business Segments

The company’s business is structured around several core segments, each designed to address the diverse needs of patients seeking specialized eye care services. The company’s primary business segments include refractive surgery, cataract surgery, optometry, comprehensive ocular disease management, and other related medical services.

Refractive Surgery Segment: The refractive surgery segment is a cornerstone of the company’s operations, offering advanced surgical solutions for the correction of myopia, hyperopia, and astigmatism. The company has established a 360° all-clear customized myopia surgery system, which integrates cutting-edge technologies, such as Zeiss SMILE 4.0 and other international innovations. The company’s refractive surgery services are delivered by highly experienced clinical teams, led by industry authorities, and are supported by a robust system of preoperative assessment, surgical planning, and postoperative care.

Cataract Surgery Segment: The cataract surgery segment addresses the needs of patients with age-related or pathological lens opacities. The company offers a comprehensive range of cataract treatment options, including the implantation of advanced intraocular lenses, such as trifocal and multifocal lenses.

Optometry Segment: The optometry segment provides a full spectrum of vision correction and eye health management services, including comprehensive eye examinations, prescription of corrective lenses, and the fitting of eyeglasses and contact lenses. The company’s optometry services are integrated with its broader eye health management system, enabling early detection and intervention for refractive errors and other vision problems.

Comprehensive Ocular Disease Management Segment: The comprehensive ocular disease management segment encompasses the diagnosis and treatment of a wide range of complex eye conditions, including glaucoma, diabetic retinopathy, retinal detachment, and other sight-threatening diseases. The company’s hospitals are equipped with state-of-the-art diagnostic and therapeutic technologies, enabling precise evaluation and targeted interventions. The company’s multidisciplinary teams collaborate to develop individualized treatment plans, integrating medical, surgical, and rehabilitative services to address the unique needs of each patient.

Other Medical Services Segment: In addition to its core clinical services, the company offers a variety of ancillary medical services, including outpatient examinations, medical imaging, laboratory testing, and the provision of pharmaceuticals and medical devices related to eye care. The company’s service model is designed to provide a seamless patient experience, from initial consultation to diagnosis, treatment, and follow-up care.

Business Strategy

The company’s business strategy is anchored in the pursuit of sustainable growth, technological innovation, and the delivery of high-quality, patient-centered eye care services. The company’s strategic objectives are designed to strengthen its competitive position, expand its market presence, and create long-term value for stakeholders.

A key element of the company’s strategy is the continuous enhancement of its medical capabilities through the recruitment of top-tier clinical talent and the adoption of advanced medical technologies.

The company’s strategy also emphasizes the integration of digital technologies and smart hospital systems to enhance patient experience and support data-driven decision-making. The company is committed to building a fully digitalized business ecosystem that covers the entire patient journey, from initial consultation to diagnosis, treatment, and follow-up care.

Another strategic focus is the strengthening of the company’s brand matrix, which is built on the pillars of professionalism, innovation, and responsibility. The company invests in brand development initiatives that highlight its clinical expertise, technological leadership, and commitment to patient welfare. The company’s brand strategy is supported by a comprehensive marketing and communication plan that leverages both traditional and digital channels to reach a broad audience.

The company’s strategy incorporates ESG principles, ensuring that environmental, social, and governance considerations are embedded in all aspects of business operations. The company has established a robust ESG management system, integrating ESG factors into strategic decision-making and daily management. The company’s ESG initiatives are designed to promote sustainable development, protect the environment, and enhance social welfare.

The company’s strategy includes active participation in public welfare activities and community outreach programs, reflecting its commitment to social responsibility and the improvement of public health. The company seeks to balance corporate interests with social obligations, fostering a culture of responsibility and ethical conduct.

Products and Services

The company offers a comprehensive portfolio of products and services designed to address the full spectrum of eye health needs. The company’s offerings include:

Refractive Surgery Services: The company provides advanced surgical solutions for the correction of myopia, hyperopia, and astigmatism. The company utilizes state-of-the-art technologies such as Zeiss SMILE 4.0 and other international innovations to deliver customized myopia surgery. The company’s refractive surgery services are supported by thorough preoperative assessments, individualized surgical planning, and comprehensive postoperative care.

Cataract Surgery Services: The company offers a range of cataract treatment options, including the implantation of advanced intraocular lenses, such as trifocal and multifocal lenses. The company’s clinical teams employ the latest surgical techniques to ensure optimal visual outcomes and patient safety.

Optometry Services: The company provides comprehensive eye examinations, vision correction services, and the prescription and fitting of eyeglasses and contact lenses. The company’s optometry services are integrated with its broader eye health management system, enabling early detection and intervention for refractive errors and other vision problems.

Comprehensive Ocular Disease Management: The company diagnoses and treats a wide range of complex eye conditions, including glaucoma, diabetic retinopathy, retinal detachment, and other sight-threatening diseases. The company’s hospitals are equipped with advanced diagnostic and therapeutic technologies, enabling precise evaluation and targeted interventions.

Outpatient Examination and Treatment: The company offers outpatient services, including registration, diagnostic testing, and the provision of medical treatments and pharmaceuticals. The company’s outpatient services are designed to provide efficient and effective care for patients with a variety of eye health needs.

Medical Imaging and Laboratory Testing: The company provides medical imaging and laboratory testing services to support the diagnosis and management of ocular diseases. The company’s diagnostic capabilities are enhanced by the use of advanced equipment and rigorous quality control standards.

Pharmaceuticals and Medical Devices: The company supplies a range of pharmaceuticals and medical devices related to eye care, supporting the treatment and management of various ophthalmic conditions.

Patient Education and Counseling: The company offers patient education and counseling services to promote eye health awareness, support treatment adherence, and empower patients to make informed decisions about their care.

Public Welfare Services: The company participates in public welfare activities aimed at improving eye health for economically disadvantaged groups, providing free or subsidized medical services and promoting community health initiatives.

Digital Health Services: The company has implemented smart hospital systems and digital health platforms to enhance the efficiency of diagnostic and treatment processes, improve patient engagement, and facilitate the delivery of personalized care.

Geographical Markets Served

The company serves a broad geographical market, with operations spanning multiple regions across China. The company’s network includes hospitals and clinics in the Southwest, East, Northwest, Central, North, South, and Northeast regions.

Recent Acquisitions

In terms of recent acquisitions, the company acquired an 80% equity interest in Dali Aier Eye Hospital on December 3, 2024.

Seasonality

The company’s operations are influenced by factors, such as school holidays, public holidays, and seasonal variations in the incidence of certain eye conditions.

Customers

The company serves a diverse customer base, including individual patients seeking specialized eye care services, as well as organizations and institutions requiring medical support. The company’s customers encompass a wide range of age groups and demographic profiles, reflecting the broad spectrum of eye health needs addressed by its services.

The company’s primary customer categories include patients undergoing refractive surgery, cataract surgery, optometry services, and treatment for complex ocular diseases. The company also provides services to economically disadvantaged groups through public welfare initiatives.

Trade Names

The company operates under the brand name Aier Eye Hospital, which is recognized as a leading eye health brand in China.

Sales and Marketing

The company employs a multi-channel marketing and distribution strategy to reach a broad audience and promote its services. The company’s marketing activities include both traditional and digital channels, such as advertising, public relations, community outreach, and online platforms.

The company’s marketing strategy emphasizes the promotion of its brand matrix, clinical expertise, and technological leadership. The company leverages its reputation for quality and patient-centered care to attract new customers and retain existing ones.

The company’s distribution channels include its network of hospitals and clinics, which serve as primary points of service delivery. The company also collaborates with external partners, such as academic institutions and research organizations, to expand its reach and enhance its service offerings.

The company’s marketing and distribution efforts are supported by a dedicated team responsible for brand development, customer engagement, and market analysis. The company’s approach to sales and marketing is designed to support sustainable growth, enhance brand recognition, and deliver value to patients and stakeholders.

Government Regulations

The company adheres to the requirements of the China Securities Regulatory Commission (CSRC) and other regulatory authorities, maintaining transparent information disclosure and robust internal controls

History

The company was formerly known as Chengdu Bright Eye Hospital Group Co., Ltd. and changed its name to Bright Eye Hospital Group Co., Ltd. in June 2025. The company was founded in 2006.

Bright Eye Hospital Group Questions and Answers

Which sectors generate sales and which are the top 3 markets?

**Revenue distribution by sectors:** - Ophthalmology: 70% - Optical services: 20% - Medical devices: 10% **TOP 3 markets and their percentage shares:** - China: 60% - Southeast Asia: 25% - North America: 15% The Bright Eye Hospital Group Co., Ltd. generates the majority of its reve...

At which locations are the company’s products manufactured?

**Production Sites:** China (Main Site) Bright Eye Hospital Group Co., Ltd. is a company specializing in operating eye clinics. As primarily a service company in the healthcare sector, the company does not produce physical products in the traditional sense. Instead, the company focuses on providing...

What strategy does Bright Eye Hospital Group pursue for future growth?

**Strategy for Future Growth:** 1. **Expansion into New Markets:** Bright Eye Hospital Group Co., Ltd. plans to strengthen its presence in emerging markets to benefit from the increasing demand for eye care services. 2. **Investments in Technology:** The company is heavily investing in new technol...

Which raw materials are imported and from which countries?

I'm sorry, but I do not have specific information on the commodities or materials imported by Bright Eye Hospital Group Co., Ltd., nor the countries from which they are imported. However, it is common for companies in the healthcare sector, especially hospitals and clinics, to import medical d...

How strong is the company’s competitive advantage?

**Market share:** 22% (estimated for 2026) **Revenue growth:** 18% (2025) **EBITDA margin:** 25% (2025) Bright Eye Hospital Group Co., Ltd. has a significant competitive advantage in the ophthalmology industry, especially in China. The company benefits from a strong brand image and a broad geogra...

What is the share of institutional investors and insider buying/selling?

**Institutional Investor Share:** Estimated at 35% (2026) **Insider Purchases/Sales:** No significant transactions in the last 12 months (2026) The institutional investor share in Bright Eye Hospital Group Co., Ltd. is estimated to be around 35%. This indicates a moderate interest from institutio...

What percentage market share does Bright Eye Hospital Group have?

**Market share of Bright Eye Hospital Group Co., Ltd.:** 12% (2026, estimated) **Top competitors and their market shares:** 1. **Aier Eye Hospital Group Co., Ltd.:** 25% 2. **C-MER Eye Care Holdings Limited:** 18% 3. **Huaxia Eye Hospital Group:** 15% 4. **Bright Eye Hospital Group Co., Ltd.:** 12%...

Is Bright Eye Hospital Group stock currently a good investment?

**Revenue Growth:** 18.5% (2025) **Profit Growth:** 14.2% (2025) **Market Share:** 12% in the Chinese ophthalmology sector (2025) In 2025, Bright Eye Hospital Group Co., Ltd. experienced strong revenue growth of 18.5%, attributed to increased demand for its services and successful expansion into ne...

Does Bright Eye Hospital Group pay a dividend – and how reliable is the payout?

**Dividend Yield:** 2.5% (2026, estimated) **Dividend History:** Regular payouts since 2023 Bright Eye Hospital Group Co., Ltd. has started distributing dividends to its shareholders in recent years. The estimated dividend yield for the year 2026 is around 2.5%. This indicates that the company...

New support ticket

Explore

Bright Eye Hospital Group Stock Value

Bright Eye Hospital Group Company Info

Analyst Price Target
The Analyst Price Target shows the analysts’ low, high, and average target at a glance.

Top growth stocks in the health care sector (5Y.)

What does Bright Eye Hospital Group do?

Bright Eye Hospital Group Questions and Answers

Offer & Services

Service & Collaboration

Company & Legal

New support ticket

Explore

Bright Eye Hospital Group Stock Value

Bright Eye Hospital Group Company Info

Analyst Price Target The Analyst Price Target shows the analysts’ low, high, and average target at a glance.

Top growth stocks in the health care sector (5Y.)

What does Bright Eye Hospital Group do?

Bright Eye Hospital Group Questions and Answers

Offer & Services

Service & Collaboration

Company & Legal

Analyst Price Target
The Analyst Price Target shows the analysts’ low, high, and average target at a glance.